Drugs / IAH0968
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05991518 | Apr 2023 → Dec 2024 | carcinoma | SUNHO（China）BioPharmaceutical CO., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04934514 | Jul 2021 → Dec 2024 | neoplasm | SUNHO（China）BioPharmaceutical CO., Ltd. | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06504732 | Aug 2024 → Jul 2028 expected | gastric neoplasm | SUNHO（China）BioPharmaceutical CO., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05673512 | May 2023 → Mar 2025 | carcinoma | SUNHO（China）BioPharmaceutical CO., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IAH0968 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04934514 ↗ |
| Modality | Monoclonal antibody | “IAH0968 is an afucosylated anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody” PMID 39676868 ↗ Nov 2024 |
| Route | Intravenous | “intravenous IAH0968” NCT05991518 ↗ |
| Target | ERBB2 | “IAH0968 is an afucosylated anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody” PMID 39676868 ↗ Nov 2024 |